Veeda Clinical Research Ltd., a full-service contract research organization (CRO), has acquired Heads, a privately held European CRO specializing in conducting clinical trials in oncology. Heads has an operational presence in 25 strategic locations across Europe, North America and the Asia Pacific region. The acquisition expands Veeda’s global reach and adds integrated capabilities for contract research services from discovery to clinical development extending to post commercial launch.
 
Dr. Mahesh Bhalgat, Group – CEO of Veeda Clinical Research, said, “With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies.”
 
Mr. Binoy Gardi, Executive Vice Chairperson of Veeda Clinical Research, said, “As we integrate the operations of both the companies, this is an exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients. We believe that our combined strengths will enable us to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide.”